Enhertu recently received Breakthrough Therapy Designation, accelerating development and review for this critical patient population
DiaMedica said it plans to launch the trial later in 2026
Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results
Designed for intense clinical environments, Rembra can handle up to 270 exams per day
Recent data reveal that patients undergoing MWL are entering aesthetic practices with unique needs tied to facial structure and skin quality
SYNT-101 is a once-daily oral pill engineered to redirect nutrient absorption beyond the small intestine’s duodenum
Zongertinib is setting a new standard as the first targeted therapy for treatment naïve patients with HER2-mutant advanced non-small cell lung cancer with demonstrated efficacy
The company said the move applies to all doses and reflects its commitment to making its medicines more affordable for patients
Under the deal, Quiver will receive an undisclosed advance payment and research support
The alliance directly links VivaMed’s computational drug hypotheses with Syngene’s preclinical development capabilities
Subscribe To Our Newsletter & Stay Updated
